LY2963016
LY2963016 is a pharmaceutical drug with 11 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 11 completed trials
Phase Distribution
Phase Distribution
6
Early Stage
0
Mid Stage
5
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
11 of 11 finished
0.0%
0 ended early
0
trials recruiting
11
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus
A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
A Study Comparing Two Formulations of Insulin Glargine in Healthy Participants
A Study in Adults With Type 2 Diabetes
Clinical Trials (11)
A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus
A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
A Study Comparing Two Formulations of Insulin Glargine in Healthy Participants
A Study in Adults With Type 2 Diabetes
A Study in Adults With Type 1 Diabetes
A Study to Compare LY2963016 and US-approved Lantus® After Single Dose Administration to Healthy Participants
A Study of LY2963016 in Healthy Participants
A Study to Compare the Pharmacokinetics and Pharmacodynamics of LY2963016 to Lantus in Healthy Participants
A Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes Mellitus
A Comparison of LY2963016 to a Basal Insulin After a Single Dose in Healthy Subjects
All 11 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 11